SilcsBio and Dalriada Drug Discovery Launch Partnership to Create a Rapid Drug Discovery Service Suite
SilcsBio and Dalriada to tap areas of expertise in drug design and development to accelerate clients’ programs in development of therapeutic treatments against diseases with unmet needs, initiated with COVID-19 FOR IMMEDIATE RELEASE: June 11, 2020, Baltimore, MD and Toronto, ON – SilcsBio, a technology company that develops innovative software and provides services for structure-based […]
Simple Synthesis of a Heterocyclophane Exhibiting Anti‐c‐Met Activity by Acting as a Hatch Blocking Access to the Active Site
Structure-Based Optimization of 10-DEBC Derivatives as Potent and Selective Pim-1 Kinase Inhibitors
Impact of Electronic Polarizability on Protein-Functional Group Interactions
Identification and characterization of fragment binding sites for allosteric ligand design using the site identification by ligand competitive saturation hotspots approach (SILCS-Hotspots)
GEn1E Lifesciences, a Y Combinator-Backed Company, Granted Exclusive License for University of Maryland, Baltimore Drug Portfolio Compound
GEn1E Lifesciences, a Y Combinator-Backed Company, Granted Exclusive License for University of Maryland, Baltimore Drug Portfolio Compound Tuesday, December 3, 2019 PALO ALTO, Calif. and BALTIMORE, Dec. 3, 2019 /PRNewswire/ — GEn1E Lifesciences Inc., a Y Combinator-backed biotech startup focused on curing inflammatory and age-related diseases, announced today that it has acquired an exclusive, worldwide and […]